F-10/A: High Tide Files $100M Shelf Prospectus, Details US Cannabis Risks

High Tide Inc. filed an amended shelf prospectus to offer up to $100 million in various securities, while detailing significant regulatory risks in its U.S. cannabis and hemp operations.

Summary

• High Tide Inc. filed an amended short form base shelf prospectus (F-10/A) to allow for the offering of up to $100,000,000 in common shares, warrants, units, subscription receipts, and debt securities over a 25-month period.
• The company operates 203 retail cannabis locations across Canada (Alberta, Ontario, Saskatchewan, Manitoba, British Columbia) and is involved in the manufacture and wholesale distribution of consumption accessories.
• Approximately 14% of assets, 6% of liabilities, and 8% of revenues for the fiscal year ended October 31, 2024, were related to the U.S. cannabis industry.
• Net cash provided by operating activities was $8,256,000 for the three months and $8,938,000 for the six months ended April 30, 2025.
• High Tide recently secured a $30 million junior secured convertible loan from a Cronos Group Inc. subsidiary, bearing 4% interest with a 5-year term, convertible into Common Shares at $4.20 per share.
• Cronos also received a warrant exercisable into 3,836,317 Common Shares at $3.91 per share.
• The company adopted a Shareholder Rights Plan on April 10, 2025, ratified by shareholders on May 29, 2025, to ensure compliance with cannabis laws and fair treatment in take-over bids.
• High Tide's U.S. operations involve the distribution of consumption accessories and Hemp-based products (CBD, Delta-9 THC products with less than 0.3% Delta-9 THC on a dry weight basis).
• The legality of cannabis remains uncertain under U.S. federal law, posing significant enforcement risks despite state-level legalization.
• The 2018 Farm Bill, which removed Hemp from the U.S. Controlled Substances Act, has been extended through September 30, 2025, but federal clarification on Hemp-derived products (CBD, Delta-8, Delta-9) remains ambiguous.
• Proposed U.S. 2026 Agriculture Spending Bill could significantly alter the federal definition of Hemp, potentially outlawing most Hemp-derived products containing quantifiable amounts of THC.
• U.K. operations for CBD products are subject to Novel Foods Regulation, with the Food Standards Agency (FSA) requiring applications for ingestible CBD products and issuing precautionary advice to limit CBD consumption to 10mg per day for healthy adults.

Sentiment

Score: 5

Explanation: The filing is a standard shelf prospectus amendment, which is generally neutral. While it highlights significant regulatory risks in the U.S. and U.K. cannabis/hemp markets, it also details a recent $30 million capital raise and positive operating cash flow, balancing the sentiment. The regulatory uncertainties, however, prevent a higher score.

Positives

• Established presence as one of Canada's largest cannabis retailers with 203 locations.
• Vertically-integrated business model, including manufacturing and wholesale distribution of consumption accessories.
• Successful capital raise of $30 million convertible debt from Cronos Group Inc., indicating investor confidence.
• Positive net cash flow from operating activities for the three and six months ended April 30, 2025 ($8,256,000 and $8,938,000 respectively).
• Proactive adoption of a Shareholder Rights Plan to protect shareholder interests and maintain license compliance.
• Ongoing monitoring of regulatory developments in both U.S. and U.K. markets.

Negatives

• Significant exposure to U.S. cannabis industry, which remains illegal under U.S. federal law, posing substantial legal and financial risks.
• Uncertainty and ambiguity in U.S. federal and state laws regarding Hemp-derived products (CBD, Delta-8, Delta-9), creating potential for enforcement actions.
• The 2018 Farm Bill, crucial for Hemp legality, has been operating under continuing resolutions and is set to expire on September 30, 2025, with potential for adverse changes in new legislation.
• Proposed U.S. 2026 Agriculture Spending Bill could significantly alter the federal definition of Hemp, potentially outlawing most Hemp-derived products containing quantifiable amounts of THC.
• U.K. regulatory intervention, including the FSA's precautionary advice to limit CBD consumption to 10mg per day and updated guidance on THC limits, could negatively impact U.K. CBD revenues.
• The postponement of DEA rescheduling proceedings for marijuana adds to regulatory uncertainty in the U.S.
• Traditional bank financing is typically unavailable for U.S. cannabis industry participants due to federal illegality, limiting capital access.
• Potential for dilution from future equity or convertible debt issuances under the shelf prospectus.

Risks

• **U.S. Federal Illegality of Cannabis**: Despite state-level legalization, cannabis remains a Schedule I controlled substance under U.S. federal law, risking prosecution, significant fines, and financial damage.
• **Uncertainty in Hemp Regulation**: Ambiguity in federal laws (2018 Farm Bill, DEA IFR, FDCA, Federal Analogue Act) regarding Hemp-derived products (CBD, Delta-8, Delta-9) creates risk of enforcement by federal agencies (DEA, FDA, FTC).
• **Changes to 2018 Farm Bill**: The 2018 Farm Bill, which defines Hemp, is subject to renewal and amendment, with potential changes (e.g., 2026 Agriculture Spending Bill) that could prohibit or significantly restrict Hemp-derived products.
• **Regulatory Enforcement in U.S.**: U.S. federal prosecutors may enforce federal laws, or interpret Hemp laws differently, leading to criminal or civil penalties, arrest of personnel, restrictions on entry to U.S., or suspension of operations.
• **FDA Regulation of Hemp-Derived Products**: FDA considers it unlawful to sell or market dietary supplements or food containing CBD or THC, and while enforcement has been limited, it remains a risk, especially for products making disease claims.
• **U.K. Novel Foods Regulation**: Ingestible CBD products in the U.K. require Novel Foods authorization; failure to obtain this for Blessed's products could lead to market withdrawal and decreased revenues.
• **U.K. FSA Consumer Advice**: New FSA advice limiting CBD consumption to 10mg/day and updated THC limits could impact product marketability and sales in the U.K.
• **Access to Capital**: Due to the federal illegality of cannabis in the U.S., traditional bank financing is generally unavailable, potentially limiting the company's ability to secure financing on favorable terms.
• **Dilution from Future Financings**: Future equity or convertible debt issuances to fund operations could result in significant dilution for existing shareholders.
• **Broad Discretion in Use of Proceeds**: Management has broad discretion over the use of net proceeds from offerings, which may not always improve operating results or enhance shareholder value.
• **Negative Cash Flow**: While currently positive, a return to negative cash flow from operations would necessitate further capital raises, subject to the aforementioned financing challenges.
• **Debt Securities Subordination**: Any unsecured debt securities would be effectively subordinated to existing and future secured debt, potentially limiting recovery in bankruptcy.
• **Epidemics and Pandemics**: Health crises could disrupt operations, reduce productivity, increase costs, and adversely affect global economies.
• **Psychoactive Hemp-Derived Products**: The sale of High THC Products (Delta-9 with <0.3% THC) that may elicit psychoactive effects carries risk of being considered illegal by state or federal regulators.
• **No Assurance of Active or Liquid Market**: No guarantee that an active or liquid trading market for Common Shares will be sustained, affecting prices.
• **Public Markets and Share Prices Fluctuations**: Market price of securities can fluctuate significantly due to operating results, financial markets, and general market conditions.
• **No Guaranteed Positive Return**: Investment in securities is speculative and involves a high degree of risk, with no guarantee of positive return.
• **Promoter Risk**: Raj Grover is considered a promoter, and details of his holdings and compensation are incorporated by reference.

Future Outlook

The company expects to continue pursuing rapid growth and strategic acquisitions, joint ventures, and investment opportunities. It anticipates positive cash flow from operating activities in future periods, though this is based on assumptions and subject to significant risks. The company intends to fund its business objectives through additional equity and/or debt financing. Regulatory clarity for Hemp-derived products in the U.S. is uncertain, with potential for new legislation (e.g., the upcoming Farm Bill) to significantly alter the definition of legal Hemp. In the U.K., the FSA is expected to validate and formally approve Novel Foods applications for CBD products by late 2025, with recommendations to Ministers in Spring/Summer 2025.

Management Comments

• Management believes that the expectations reflected in these forward-looking statements are reasonable in light of, among other things, its perception of trends, current conditions and expected developments, as well as other factors that Management believes to be relevant and reasonable in the circumstances at the date that such statements are made.
• The Corporation and Management believe that the FOFI has been prepared on a reasonable basis, reflecting Managements best estimates and judgments as at the applicable date.
• The Board believe that it is not scientifically or technologically possible to remediate these samples any further in private business operations.
• The Board expects the FSA to validate those products marked as awaiting evidence by late 2025. The Board expects the FSA to formally approve the applications by the end of 2025. However, the Board notes that the FSA has not provided any timeline.
• The Board considers that this underscores the gravity of the FSA's regulations and their impact on the industry.

Industry Context

The filing highlights the ongoing conflict between U.S. federal and state laws regarding cannabis, a critical challenge for companies with U.S. cannabis-related operations. The uncertainty surrounding the 2018 Farm Bill's renewal and potential changes in the 2026 Agriculture Spending Bill reflects a broader industry trend of evolving and unpredictable regulatory landscapes for Hemp-derived products. In the U.K., the increasing regulatory scrutiny on CBD products, particularly the Novel Foods regime and FSA's consumption limits, indicates a global trend towards stricter oversight of the wellness cannabis market. The postponement of DEA rescheduling proceedings for marijuana further underscores the slow and uncertain pace of federal reform in the U.S. cannabis industry.

Corporate Governance

Related Party Transactions

• A loan agreement was entered into with a wholly owned subsidiary of Cronos Group Inc. for a $30 million junior secured convertible loan, bearing 4% interest with a 5-year term, convertible into Common Shares at $4.20 per share. Cronos also received a warrant exercisable into 3,836,317 Common Shares at $3.91 per share.

Stakeholder Impact

• **Shareholders**: Potential for dilution from future equity offerings; protection from unsolicited take-over bids via Shareholder Rights Plan; exposure to significant regulatory risks in U.S. and U.K. markets.
• **Customers**: Continued access to a wide range of cannabis products in Canada and consumption accessories/Hemp-derived products in the U.S. and U.K.; potential impact on product availability or formulation due to evolving U.K. CBD regulations (e.g., 10mg/day limit).
• **Employees**: Potential impact from U.S. federal enforcement actions, including arrests or restrictions on entry to the U.S.
• **Creditors**: The $30 million junior secured loan from Cronos Group Inc. adds to the company's debt structure; unsecured debt securities would be subordinated to secured debt.
• **Regulatory Bodies**: Ongoing engagement and compliance efforts with Canadian, U.S. (federal and state), and U.K. (FSA, MHRA) regulatory frameworks.

Next Steps

• Issuance of prospectus supplements for specific offerings of securities under the $100,000,000 shelf registration.
• Management will retain broad discretion in allocating net proceeds from any future offerings.
• Continued active pursuit of acquisition, joint venture, and investment opportunities.
• Monitoring of regulatory developments in the U.S. and U.K. cannabis and Hemp industries.
• FSA to continue risk assessment and management process for U.K. Novel Foods applications, with recommendations to Ministers in Spring/Summer 2025 and expected formal approval by end of 2025.
• DEA rescheduling proceedings for marijuana are ongoing, with a new hearing date yet to be announced.
• U.S. Congress to address the renewal of the 2018 Farm Bill and potential changes in the 2026 Agriculture Spending Bill.
• Company to make product and packaging changes to meet updated FSA guidance on THC and CBD limits in the U.K.

Key Dates

Recommendation

The filing outlines a strategic move to secure future capital through a shelf prospectus and details a recent $30 million convertible debt financing, which provides liquidity. The company demonstrates strong operational presence in Canada and positive operating cash flow. However, significant regulatory uncertainties and risks in the U.S. cannabis and Hemp markets, including potential adverse changes to federal laws and ongoing DEA rescheduling delays, create substantial headwinds. The evolving U.K. CBD regulations also pose challenges. Given the balance of strategic financing and operational strength against considerable regulatory risks, a 'hold' recommendation is appropriate until there is greater clarity on the U.S. federal regulatory landscape and the impact of U.K. CBD rules.

Keywords

Cannabis Retail, Hemp Products, CBD, Delta-9 THC, SEC Filing, Shelf Prospectus, Capital Raise, Regulatory Risk, Canada Cannabis, US Cannabis Law, UK CBD Market, High Tide Inc., HITI, Convertible Debt, Shareholder Rights Plan, Financial Reporting, Investment Risk